Aktana Named a Leader and Star Performer in Everest Group’s 2024 Life Sciences Next-generation Customer Engagement Platforms (CEPs) PEAK Matrix®
Aktana, the leader in AI-driven intelligent engagement for the life sciences industry, today announced its recognition as a Leader and one of only three Star Performers in the 2024 Life Sciences Next-generation CEPs PEAK Matrix® by Everest Group. Advancing from 2023 “Major Contenders” to 2024 “Leader and Star Performer,” this ongoing recognition highlights Aktana’s commitment to driving innovation and measurable impact for its global customers.
"Life Sciences enterprises are increasingly prioritizing experience-driven Customer Engagement Platforms (CEPs) over traditional CRM systems, reflecting a significant shift towards customer-centric strategies. The focus is on leveraging real-time insights, dynamic content management, and AI-driven functionalities, to enhance customer interactions across diverse stakeholder segments, including sales, marketing, medical affairs, and patient services," says Chunky Satija, Vice President, Healthcare and Life Sciences, Everest Group.
Satija continues: "Aktana provides a robust suite of life sciences-focused customer engagement solutions that incorporate advanced features, such as KPI improvement tactics, strategy formulation and execution, and next-best-action recommendations, enabling enterprises to enhance customer engagement through performance tracking and proactive insights. Clients appreciate the user-friendly interface that provides seamless functionality across devices. As a result, Aktana has earned recognition as a Leader and Star Performer in the 2024 Life Sciences Next-generation Customer Engagement Platforms (CEPs) PEAK Matrix® Assessment.”
Everest Group highlighted Aktana’s transformative advancements, including its best-in-class Orchestration, which ensures brand strategy-led execution across channels while optimizing ROI. They also called out Aktana’s focus on integrations and CRM-agnostic design, enabling migration to new CRMs like Veeva Vault CRM and Salesforce Life Sciences Cloud without disrupting operations in evolving CRM ecosystems. Buyers also considered Aktana’s pricing to be “fair and competitive”.
John Vitalie, CEO of Aktana, added: “We are honored to be named both a Leader and Star Performer by Everest Group. Aktana is helping to lead the transformation to true AI-driven omnichannel capabilities in partnership with our customers. We look forward to building on this momentum to generate more value as our customers scale.”
This achievement builds on the success of Aktana’s collaboration with leading life sciences companies. A recent client study demonstrated how Aktana’s AI-driven recommendations enabled commercial teams for that client to achieve more than half a billion dollars in annual incremental revenue, as independently verified.
Download: https://go.aktana.com/everest-group-life-sciences-next-generation-customer-engagement/
About Aktana
Aktana provides AI-powered solutions tailored to the life sciences industry, enabling commercial teams to align strategies with customer needs, optimize engagement across channels, and deliver measurable impact. Aktana’s ability to blend advanced technology with a client-centric approach has made it a trusted partner to support over 300 life sciences brands globally.
For more information, visit www.aktana.com.
LinkedIn: www.linkedin.com/company/aktana
Twitter: www.twitter.com/aktana_inc
Disclaimer
Licensed extracts taken from Everest Group’s PEAK Matrix® Reports, may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group’s PEAK Matrix® reports do not necessarily provide the full context of our research and analysis. All research and analysis conducted by Everest Group’s analysts and included in Everest Group’s PEAK Matrix® reports is independent and no organization has paid a fee to be featured or to influence their ranking. To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix® Reports.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241118405501/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release
- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc
Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 14:00:00 CEST | Press release
Pivotal Study Advances to Establish Histotripsy as a Non-Thermal, Surgery-Free Alternative to Destroy and Liquefy Kidney Tumors HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison
Norwegian Tech Firm Builds Military Command Center in 24 Hours6.6.2025 13:45:00 CEST | Press release
Norwegian technology provider Cyviz has successfully developed a fully mobile and ballistic-proof command center - designed, configured, and made operational in just 24 hours. The solution was showcased during a military exercise led by the Dutch Ministry of Defence and has already sparked interest from NATO members and civil protection agencies across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606640770/en/ Cyviz demonstrates rapid deployment capability with a mobile, container-based control room for defense and crisis response Cyviz and its partners constructed the command room inside a 14-ton container designed for transport on standard military vehicles and resistant to machine gun fire. The unit was deployed at a military base in the Netherlands, where Cyviz was tasked with delivering a fully functional command-and-control environment, under strict time constraints and in a high-stakes simulation. "You do
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom